Fuzeon
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
The failures of several first‐generation and second‐generation small molecule drug‐based anti‐HIV therapies in various stages of…
Fuzeon (Enfuvirtide, T20) is the first fusion inhibitor approved by the FDA of the USA for the treatment of HIV/AIDS in…
Bone scintigraphy using Tc-99m methylene diphosphonate (MDP) was performed on a 16-year-old girl as a component of surveillance…
Enfuvirtide (ENF, T-20, or Fuzeon [Hoffman-La Roche Inc, Nutley, NJ, and Trimeris, Inc, Durham, NC]) is an HIV-1 fusion inhibitor…
The FDA changed the FUZEON prescribing information to help avoid this common and unpleasant side effect of the drug.
In recent years, significant progress has been made towards the chemotherapy (and ?prophylaxis) of HIV infections. This progress…
Zusammenfassung.Hintergrund:Die hochaktive antiretrovirale Therapie (HAART) hat die Mortalitätsrate von AIDS-Patienten in den…
With the number of people living with HIV infection increasing and the problems of drug resistance and long‐term toxicity…
The FDA approved enfuvirtide (Fuzeon) in spring 2003 to use with other anti-HIV drugs in children age six and older and in adults…